New drug classes for the treatment of partial onset epilepsy

Focus on perampanel

Jerry J. Shih, William O. Tatum, Leslie Ann Rudzinski

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest in the line of new antiepileptic drugs with a novel mechanism of action. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increases in intracellular Ca2+ and selectively blocks AMPA receptor-mediated synaptic trans-mission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States, with expected release onto the American market in June-September 2013, pending US Drug Enforcement Agency classification. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy. As an AMPA-receptor antagonist, perampanel may possess antiepileptogenic properties in addition to its demonstrated antiseizure properties.

Original languageEnglish (US)
Pages (from-to)285-293
Number of pages9
JournalTherapeutics and Clinical Risk Management
Volume9
Issue number1
DOIs
StatePublished - Aug 21 2013

Fingerprint

Propionic acid
epilepsy
Partial Epilepsy
Hydrates
Refractory materials
drug
Pharmaceutical Preparations
AMPA Receptors
Anticonvulsants
Isoxazoles
Therapeutics
pharmacology
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
seizure
European Union
Seizures
Placebos
perampanel
Pharmacology
market

Keywords

  • Efficacy
  • Mechanism of action
  • Perampanel
  • Review

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

New drug classes for the treatment of partial onset epilepsy : Focus on perampanel. / Shih, Jerry J.; Tatum, William O.; Rudzinski, Leslie Ann.

In: Therapeutics and Clinical Risk Management, Vol. 9, No. 1, 21.08.2013, p. 285-293.

Research output: Contribution to journalReview article

Shih, Jerry J. ; Tatum, William O. ; Rudzinski, Leslie Ann. / New drug classes for the treatment of partial onset epilepsy : Focus on perampanel. In: Therapeutics and Clinical Risk Management. 2013 ; Vol. 9, No. 1. pp. 285-293.
@article{5b061c3a9575410b8ee22acf63f9d6f4,
title = "New drug classes for the treatment of partial onset epilepsy: Focus on perampanel",
abstract = "Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest in the line of new antiepileptic drugs with a novel mechanism of action. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increases in intracellular Ca2+ and selectively blocks AMPA receptor-mediated synaptic trans-mission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States, with expected release onto the American market in June-September 2013, pending US Drug Enforcement Agency classification. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy. As an AMPA-receptor antagonist, perampanel may possess antiepileptogenic properties in addition to its demonstrated antiseizure properties.",
keywords = "Efficacy, Mechanism of action, Perampanel, Review",
author = "Shih, {Jerry J.} and Tatum, {William O.} and Rudzinski, {Leslie Ann}",
year = "2013",
month = "8",
day = "21",
doi = "10.2147/TCRM.S37317",
language = "English (US)",
volume = "9",
pages = "285--293",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - New drug classes for the treatment of partial onset epilepsy

T2 - Focus on perampanel

AU - Shih, Jerry J.

AU - Tatum, William O.

AU - Rudzinski, Leslie Ann

PY - 2013/8/21

Y1 - 2013/8/21

N2 - Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest in the line of new antiepileptic drugs with a novel mechanism of action. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increases in intracellular Ca2+ and selectively blocks AMPA receptor-mediated synaptic trans-mission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States, with expected release onto the American market in June-September 2013, pending US Drug Enforcement Agency classification. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy. As an AMPA-receptor antagonist, perampanel may possess antiepileptogenic properties in addition to its demonstrated antiseizure properties.

AB - Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest in the line of new antiepileptic drugs with a novel mechanism of action. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increases in intracellular Ca2+ and selectively blocks AMPA receptor-mediated synaptic trans-mission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States, with expected release onto the American market in June-September 2013, pending US Drug Enforcement Agency classification. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy. As an AMPA-receptor antagonist, perampanel may possess antiepileptogenic properties in addition to its demonstrated antiseizure properties.

KW - Efficacy

KW - Mechanism of action

KW - Perampanel

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=84881582057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881582057&partnerID=8YFLogxK

U2 - 10.2147/TCRM.S37317

DO - 10.2147/TCRM.S37317

M3 - Review article

VL - 9

SP - 285

EP - 293

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 1

ER -